Login to Your Account



Clinic Roundup


Monday, August 19, 2013
• Prosonix, of Oxford, UK, completed patient dosing and follow-up in a Phase II study of PXS1002, a suspension formulation of long-acting muscarinic antagonist (LAMA), glycopyrronium bromide, which is being developed for chronic obstructive pulmonary disease (COPD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription